Progress and prospects in vaccine therapy for gynecologic cancers

ONCOLOGY

Volumn 11, Issue 11, 1997, Pages 1727-1740

  Gurski, Karen J ^a,b   Steller, Michael A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT INTERLEUKIN 2; VIRUS PROTEIN;

CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; FEMALE; FEMALE GENITAL TRACT CANCER; GENE THERAPY; GYNECOLOGIC CANCER; HUMAN; IMMUNOMODULATION; OVARY CANCER; REVIEW; T LYMPHOCYTE; UTERINE CERVIX CANCER; UTERUS CANCER; VACCINATION; VULVA CANCER; WART VIRUS;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; GENE THERAPY; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0030684783     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Pardoll, DM: Genetically engineered tumor vaccines, Ann N Y Acad Sci 690:301-310, 1993.
2. Schiller JT, Okun MM: Papillomavirus vaccines: current status and future prospects. Adv Dermatol 11: 355-380, 381, 1996
3. Whalen RG, Davis HL: DNA-mediated immunization and the energetic immune response to hepatitis B surface antigen. Clin Immunol Immunopathol 75:1-12, 1995.
4. Melief CJ: Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 58:143-175, 1992.
5. Melief CJ, Kast WM: Lessons from T cell responses to vires-induced tumors for cancer eradication in general. Cancer Surv 13:81-99, 1992.
6. Neefjes JJ, Momburg F: Cell biology of antigen presentation. Curr Opin. Immunol 5:27-34, 1993.
7. Keating PJ, Cromme FV, Duggan-Keen M, et al: Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 72:405- 411, 1995.
8. Garrido F, Ruiz-Cabello F, Cabrera T, et al: Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 18:89-95, 1997.
9. Old LJ: Immunotherapy for cancer. Sci Am 275:136-143, 1996.
10. Irvine KR, Restifo NP: The next wave of recombinant and synthetic anticancer vaccines. Semin Cancer Biol 6:337-347, 1995.
11. Roitt I, Brostoff J, Male D. Cells involved in the immune response, in Foley F, van den Bergh L, Welcomme C (eds): Immunology, pp 1-18. New York, Mosby, 1989.
12. Gabrilovich DI, Ciernik IF, Carbone DP: Dendritic cells in antitumor immune responses. I. Detective antigen presentation in tumor-bearing hosts. Cell Immunol 170:101-110, 1996.
13. Porgador A, Snyder D, Gilboa E: Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156:2918-2926, 1996.
14. Zinkernagel RM: Immunology taught by viruses. Science 271:173-178, 1996.
15. Lodish H, Baltimore D, Berk D, et al: Molecular Cell Biology, 3rd ed, New York, Scientific American Books, Inc. 1995.
16. Oliff A, Gibbs JB, McCormick F: New molecular targets for cancer therapy. Sci Am 275:144-149, 1996
17. Yoshino I, Peoples GE, Goedegebuure PS, et al: Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 152:2393-2400, 1994.
18. Restifo, NP: The new vaccines: building viruses that elicit antitumor immunity. Curr Opin Immunol 8:658-663, 1996.
19. Vitiello A, Ishioka G, Grey HM, et al: Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 95:341-349, 1995.
20. Alexander J, Sidney J, Southwood S, et al: Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751-761, 1994
21. Steller MA, Schiller, JT: Human papillomavirus immunology and vaccine prospects. J Natl Cancer Inst Monogr 21:145-148, 1996.
22. Trudel M, Nadon F, Segum C, et al: Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine. Vaccine 10:107-112, 1992.
23. Morein B: The ISCOM antigen-presenting system. Nature 332:287-288, 1988.
24. Fernando GJ, Stenzel DJ, Tindle RW, et al: Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production. Vaccine 13:1460-1467, 1995.
25. Barr IG, Mitchell GF: ISCOMs (immunostimulating complexes): the first decade. Immunol Cell Biol 74:8-25, 1996.
26. Mackett M, Smith GL, Moss B: Vaccinia virus: a selectable cukaryotic cloning and expression vector. Proc Natl Acad Sci USA 79:7415-7419, 1982.
27. Bosch FX, Manos MM, Munoz N, et al: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective International biological study on cervical cancer (IBSCC) Study Group [see comments]. J Natl Cancer Inst 87:796-802, 1995.
28. de Villiers EM: Heterogeneity of the human papillomavirus group. J Virol 63:4898-4903, 1989.
29. Munger K, Phelps WC, Bubb V, et al: The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63:4417-4421, 1989
30. Crook T, Morgenstern JP, Crawford L, et al: Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J 8:513-519, 1989.
31. Kast WM, Brandt RM, Sidney I, et al: Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 152:3904-3912, 1994.
32. Ressing ME, Sette A, Brandt RM, et al: Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154:5934-5943, 1995.
33. Feltkamp MC, Smits HL, Vierboom MP, et al: Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol: 23:2242-2249, 1993.
34. Alexander M, Salgaller ML, Celis E, et al: Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am J Obstet Gynecol 175:1586-1593, 1996.
35. Martinez-Kinader B, Lipford GB, Wagner H, et al: Sensitization of MHC class I-restrictcd T cells to exogenous proteins: evidence for an alternative class I-restricted antigen presentation pathway. Immunology 86:287-295, 1995.
36. Schirmbeck R, Deml L, Melber K, et al: Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. Vaccine 13:857-865, 1995.
37. Borysiewicz LK, Fiander A, Nimako M, et al: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [see comments]. Lancet 347:1523-1527, 1996.
38. Irvine KR, McCabe BJ, Rosenberg SA, et al: Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL J. Immunol 154:4651-4657, 1995.
39. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al: Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 92:11671-11675, 1995.
40. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21-26, 1996.
41. Kirnbauer R, Booy F, Cheng N, et al: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89:12180-12184, 1992.
42. Kirnbauer R, Taub J, Greenstone H, et al: Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67:6929-6936, 1993.
43. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al: Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92:11553-11557, 1995.
44. Brinton LA: Epidemiology of cervical cancer - overview. IARC Sci Publ. 3:23, 1992
45. Hacker NF: Vulvar cancer, in Berek JS, Hacker NF (eds): Practical Gynecologic Oncology, pp 403-440. Baltimore, Williams & Wilkins, 1994.
46. Hording U, Junge J, Poulsen H, et al: Vulvar intraepithelial neoplasia III: a viral disease of undetermined progressive potential. Gynecol Oncol 56:276-279, 1995.
47. Rusk D, Sutton GP, Look KY, et al: Analysis of invasive squamous-cell carcinoma of the vulva and vulvar intraepithelial neoplasia for the presence of human papillomavirus DNA. Obstet Gynecol 77:918-922, 1991.
48. Kim YT, Thomas NF, Kessis TD, et al: p53 mutations and clonality in vulvar carcinomas and squamous hyperplasias: evidence suggesting that squamous hyperplasias do not serve as direct precursors of human papillomavirus-negative vulvar carcinomas. Hum Pathol 27:389-395, 1996.
49. Ciernik IF, Berzofsky J, Carbone, DP: Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53. Hybridoma 14:139-142, 1995.
50. Katsaros D, Theillet C, Zola P, et al: Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients Anticancer Res 15:1501-1510, 1995.
51. Barnes MN, Deshane JS, Rosenfeld M, et al: Gene therapy and ovarian cancer, a review. Obstet Gynecol 89:145-155, 1997.
52. Coney LR, Tomassetti A, Carayannopoulos L, et al: Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 51:6125-6132, 1991.
53. Canevari S, Stoter G, Arienti F, et al: Regression of advanced ovarian carcinoma by intra-peritoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87:1463-1469, 1995.
54. Hwu P, Yang JC, Cowherd R, et al: In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55:3369-3373, 1995.
55. Deshane J, Loechel F, Conry RM, et al: Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther 1:332-337, 1994
56. Stewart JA, Belinson JL, Moore AL, et al: Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 50:6302-6310, 1990.
57. Berchuck A, Lyerly HK: A phase I study of autologous human interleukin-2 (IL-2) gene modified tumor cells in patients with refractory metastatic ovarian cancer (abstract) Human Gene Transfer Protocols. Office of Recombinant DNA Activities, National Institutes of Health, 1995.
58. Dorigo O, Fakhrai H, Shawler D, et al: Development of a genetically- modified tumor cell vaccine for ovarian cancer using IL-2 gene transfer combined with TGF-beta antisense modification (abstract 401997). Proc Soc Gynecol Oncol, 1997.
59. Peoples GE, Goedegebuure PS, Smith R: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92:432-436, 1995.
60. Lacy MQ, Hartmann LC, Keeney GL, et al: c-erbB-2 and p53 expression in fallopian tube carcinoma. Cancer 75:2891-2896, 1995.
61. Mizuuchi H, Mori Y, Sato K, et al: High incidence of point mutation in K-ras codon 12 in carcinoma of the fallopian tube. Cancer 76:86-90, 1995.
62. Berchuck A: Biomarkers in the endometrium. J Cell Biochem 23(suppl):174-8:174-178, 1995.
63. Tateno H, Yamada M, Funaki K: Chromosomal characteristics of tumorigenic cells derived from a spontaneous uterine leiomyosarcoma of the Chinese hamster. Cancer Genet Cytogenet 79:54-58, 1995.
64. Goletz TJ, Zhan S, Pendleton CD, et al: Cytotoxic T cell responses against the EWS/FLI-1 Ewing's sarcoma fusion protein and the PAX3/FKJR alveolar rhabdomyosarcoma fusion protein (abstract). Proc Am Assoc Cancer Res. 37:475, 1997.
65. Huang Y, Saez R, Chao L, et al: A novel insertional mutation in the TC21 gene activates its transforming activity in a human leiomyosarcoma cell line. Oncogene 11:1255-1260, 1995.